PT2994160T - Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada - Google Patents

Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada

Info

Publication number
PT2994160T
PT2994160T PT14730660T PT14730660T PT2994160T PT 2994160 T PT2994160 T PT 2994160T PT 14730660 T PT14730660 T PT 14730660T PT 14730660 T PT14730660 T PT 14730660T PT 2994160 T PT2994160 T PT 2994160T
Authority
PT
Portugal
Prior art keywords
alzheimer
treatment
pooled immunoglobulin
subpopulations
disease
Prior art date
Application number
PT14730660T
Other languages
English (en)
Portuguese (pt)
Inventor
M Gelmont David
Singer Julia
Fritsch Sandor
Schwarz Hans-Peter
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Publication of PT2994160T publication Critical patent/PT2994160T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT14730660T 2013-05-06 2014-05-05 Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada PT2994160T (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361855062P 2013-05-06 2013-05-06
US201361833447P 2013-06-10 2013-06-10
US201361844732P 2013-07-10 2013-07-10
US201361886464P 2013-10-03 2013-10-03

Publications (1)

Publication Number Publication Date
PT2994160T true PT2994160T (pt) 2019-08-07

Family

ID=50943566

Family Applications (1)

Application Number Title Priority Date Filing Date
PT14730660T PT2994160T (pt) 2013-05-06 2014-05-05 Tratamento de sub-populações com doença de alzheimer com imunoglobulina g combinada

Country Status (12)

Country Link
US (3) US20140328856A1 (enExample)
EP (2) EP2994160B1 (enExample)
JP (1) JP6424210B2 (enExample)
AU (4) AU2014262890B2 (enExample)
DK (1) DK2994160T3 (enExample)
ES (1) ES2740127T3 (enExample)
HR (1) HRP20191383T1 (enExample)
HU (1) HUE044737T2 (enExample)
LT (1) LT2994160T (enExample)
PL (1) PL2994160T3 (enExample)
PT (1) PT2994160T (enExample)
WO (1) WO2014182631A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4289820A3 (en) 2014-03-21 2024-03-13 Alzheon, Inc. Compounds for use in treating alzheimer's disease in apoe4+/+ patients
WO2016033382A1 (en) * 2014-08-27 2016-03-03 Capnia, Inc. Methods for immune globulin administration
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
JP6789579B2 (ja) * 2015-09-10 2020-11-25 アルジオン， インコーポレイテッド 特定の患者集団において神経変性障害を処置する方法
CN114019170A (zh) * 2016-01-20 2022-02-08 基因泰克公司 用于阿尔茨海默氏病的高剂量治疗
HRP20211628T1 (hr) * 2016-08-18 2022-02-04 Alkahest, Inc. Frakcije krvne plazme kao tretman za kongitivne poremećaje povezane sa starenjem
BR112019022402A2 (pt) * 2017-04-26 2020-05-19 Alkahest Inc regime de dosagem para tratamento de comprometimentos cognitivo e motor com plasma sanguíneo e produtos de plasma sanguíneo
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
SI3672631T1 (sl) 2017-08-22 2023-06-30 Biogen Ma Inc. Farmacevtski sestavki, ki vsebujejo protitelesa proti beta amiloidu
FI128916B (en) * 2018-02-05 2021-03-15 Vetcare Oy Health-promoting composition and method for its preparation
KR102276545B1 (ko) * 2019-09-05 2021-07-15 고려대학교 산학협력단 Ct 영상 기반 부위별 대뇌 피질 수축율 예측 방법 및 장치
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
CA3198827A1 (en) * 2020-10-30 2022-05-05 Rush University Medical Center Intranasal immunotherapy for the treatment of alzheimer's disease
EP4472679A1 (en) * 2022-02-03 2024-12-11 Eli Lilly and Company Regional tau imaging for diagnosing and treating alzheimer's disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (enExample) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
WO2003028668A2 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. Gammaglobulin treatment of immune disorders
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
WO2006091332A2 (en) 2005-02-23 2006-08-31 Alza Corporation Intranasal administration of active agents to the central nervous system
PL1981540T3 (pl) * 2006-01-30 2013-08-30 Grifols Therapeutics Inc Sposób leczenia i profilaktyki chorób związanych z odkładaniem się amyloidu z zastosowaniem IgM
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
US9084743B2 (en) 2009-09-17 2015-07-21 Baxter International Inc. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
US8622993B2 (en) 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
SG184820A1 (en) * 2010-04-13 2012-11-29 Baxter Int Use of ventricular enlargement rate in intravenous immunoglobulin treatment of alzheimer's disease
WO2011142778A1 (en) * 2010-05-13 2011-11-17 The University Of Kentucky Research Foundation Treatment of mci and alzheimer's disease
JP6055412B2 (ja) * 2010-09-17 2016-12-27 バクスアルタ ゲーエムベーハー 弱酸性〜中性のｐＨにおける、ヒスチジンを有する水性製剤を介した免疫グロブリンの安定化
KR20130139153A (ko) * 2011-01-18 2013-12-20 백스터 인터내셔널 인코포레이티드 인간 혈액 중 항-베타 아밀로이드 항체의 측정
US20120251524A1 (en) * 2011-04-01 2012-10-04 Baxter Healthcare S.A. Use of cytokine levels in intravenous immunoglobulin treatment of alzheimer's disease
ES2714999T3 (es) * 2011-09-24 2019-05-31 Csl Behring Gmbh Terapia de combinación que usa inmunoglobulina e inhibidor de C1

Also Published As

Publication number Publication date
AU2014262890A1 (en) 2015-11-26
PL2994160T3 (pl) 2019-10-31
JP6424210B2 (ja) 2018-11-14
AU2019202459A1 (en) 2019-05-02
AU2024201051A1 (en) 2024-03-14
HRP20191383T1 (hr) 2020-02-07
ES2740127T3 (es) 2020-02-05
LT2994160T (lt) 2019-08-26
DK2994160T3 (da) 2019-08-12
US20140328856A1 (en) 2014-11-06
US20210238267A1 (en) 2021-08-05
EP2994160B1 (en) 2019-07-03
AU2020257034A1 (en) 2020-11-12
WO2014182631A1 (en) 2014-11-13
EP3552624A1 (en) 2019-10-16
EP2994160A1 (en) 2016-03-16
AU2014262890B2 (en) 2019-01-31
JP2016518411A (ja) 2016-06-23
US20190144530A1 (en) 2019-05-16
HUE044737T2 (hu) 2019-11-28
AU2019202459B2 (en) 2020-07-23

Similar Documents

Publication Publication Date Title
HUE044737T2 (hu) Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
IL266648B (en) A method for treating Parkinson's disease
IL245643A0 (en) Install closure between mri and incubator
IL240511A0 (en) Human antibodies to nav1.7
HUE061618T2 (hu) Vegyület szemrendellenességek kezelésére
EP2951139A4 (en) SYNTHESIS FROM 1,1,2,3-TETRACHLORPROPENE
EP2970511A4 (en) INSULIN CONJUGATES incretin
EP2971491A4 (en) MEASURING A HOUSING WEAR
EP2971207A4 (en) PREPARATION OF ALUMINUM SCANDIUM ALLOYS
IL242293B (en) Bacteriophage therapy
GB201310150D0 (en) Methods and compositions relating to alzheimer's disease
EP3086846A4 (en) Diagnosing and treating alzheimer's disease
HUE045148T2 (hu) Bumetanid parkinson-szindrómás neurodegeneratív betegségek kezelésére
IL243637B (en) PPAR-sparing compounds for the treatment of metabolic diseases
EP2958454A4 (en) MAGNETOTHERAPEUTIC BAND
GB201311036D0 (en) Biomarkers for alzheimer's Disease
LT3148588T (lt) N,n-bis-2-merkaptoetilizoftalamidas, skirtas parkinsono ligos gydymui
HK40032828A (en) Methods for the treatment of mitochondrial disease
IL241482A0 (en) A method for treating Parkinson's disease
GB201310101D0 (en) Treatment of freidreich's ataxia
GB201304393D0 (en) Time's tremor
UA26689S (uk) Ущільнювач з'єднань механізмів транспортного засобу
BR302013002169S1 (pt) "configuração aplicada em odorizador automotivo"
GB201306413D0 (en) The local treatment of ophthalmic diseases
GB201511453D0 (en) Treatment of alzheimer's disease